Data / Crowdfunding / Texas / AlphaRose Therapeutics Inc
AlphaRose Therapeutics Inc: crowdfunding raise on StartEngine Primary, LLC, $19,998 to $4,999,999 (2025)
AlphaRose Therapeutics Inc, a corporation in Austin, TX, filed a Form C with the SEC on August 27, 2025 to raise $19,998 to $4,999,999 in common stock through StartEngine Primary, LLC. The offering closed on September 29, 2025. In its most recent fiscal year it reported $0 in revenue and a net loss of $625,253, with 1 employees.
SpecStream is the live web data engine for teams and agents. It reads every Form C on SEC EDGAR each morning, and this page is that reading. Ask for your own cut (a portal, a state, a size, a revenue range) and new raises arrive in your sheet, CRM, Slack or agent as they land.
- Website
- www.alpharose.com
- Funding portal
- StartEngine Primary, LLC
- Address
- 1401 LAVACA STREET, #851, Austin, TX 78701
- Legal form
- Corporation
- Jurisdiction
- DE
- Incorporated
- October 31, 2023
- SEC CIK
- 0002051498
Offering terms
From the amendment filed August 27, 2025.
- Security
- Common Stock
- Price
- $1.35
- Target
- $19,998
- Maximum
- $4,999,999
- Deadline
- September 29, 2025
- Portal compensation
- 7 - 13 percent
Financials
From the Form C-U filed October 6, 2025.
| Most recent fiscal year | Prior fiscal year | Source | |
|---|---|---|---|
| Revenue | $0 | $0 | sec.gov |
| Cost of goods sold | $0 | $0 | sec.gov |
| Net income | $-625,253 | $0 | sec.gov |
| Taxes paid | $0 | $0 | sec.gov |
| Total assets | $614,498 | $0 | sec.gov |
| Cash | $525,845 | $49,990 | sec.gov |
| Accounts receivable | $0 | $0 | sec.gov |
| Short-term debt | $81,098 | $0 | sec.gov |
| Long-term debt | $1,151,098 | $0 | sec.gov |
Filings
| Filed | Filing | Target | Maximum | Deadline | Note | Source |
|---|---|---|---|---|---|---|
| October 6, 2025 | Progress update | $19,998 | $4,999,999 | September 29, 2025 | At the close of the offering, the issuer closed on $1,583,596.78 anhd 1,812,846 number of securities. | sec.gov |
| August 27, 2025 | Amendment | $19,998 | $4,999,999 | September 29, 2025 | Issuer is updating their offering end date to September 29, 2025. | sec.gov |
| August 14, 2025 | Amendment | $19,998 | $4,999,999 | August 28, 2025 | Issuer is updating their campaign page | sec.gov |
| June 17, 2025 | Amendment | $19,998 | $4,999,999 | August 28, 2025 | Issuer is extending their end date to August 28th, 2025, disclosing the acquisition of Alpha Anomeric SA, and disclosing the appointment of Lance Hirsch. | sec.gov |
| April 29, 2025 | Annual report | Not listed | Not listed | sec.gov | ||
| March 18, 2025 | Amendment | $19,998 | $4,999,999 | June 17, 2025 | Audited financials for FY 12/31/24 & 12/31/23 completed; prior year adjusted. Cash on hand updated to Feb 2025. Added disclosures on product status, FDA process, IP, insider investments ($6,199.20), funding goals, use of proceeds & extended end date. | sec.gov |
| January 29, 2025 | Offering | $123,998 | $1,234,997 | April 30, 2025 | sec.gov |
Updated October 6, 2025. Read from SEC EDGAR. Public domain (U.S. government work). Financials are as each company reported them in its Form C, unaudited unless the filing says otherwise. Websites are the ones the companies declared to the SEC. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.